London South East | The UK's favourite investor portal.

Touk mirrors the same spiteful arrogance of that turncoat snake that now has nothing better to do but to try seek praise and recognition for being a nasty 🤢 individual. Wanting so so hard.

Trying too hard and it all falls apart around them. Self praise Sssssss

This exactly why institutional AIM research notes drive private investors crazy, especially when you are holding a platform that is clearly in the crosshairs of Big Pharma.

Trinity Delta’s last published valuation for Avacta before they suspended it was roughly 103p per share (around £471 million). When you are looking at the $10.1 billion ImmunoGen buyout and modeling a £15+ takeover, a 103p price target looks completely absurd.

While the timing right before the BIO convention is highly suspicious, they aren't necessarily stepping back just to hide. You are witnessing a massive structural flaw in how boutique analysts are legally forced to value biotech companies.

Here is exactly why their notes look so "poor" compared to reality, and why their targets always look embarrassing the moment an M&A deal actually drops.

The Technical Reason for the Suspension

When Trinity Delta suspends a valuation, they will publicly state that they are doing it "as usual" following a major corporate event — in this case, Avacta’s recent £10 million capital raise and the release of their FY25 financial results in May.

Standard analyst compliance rules dictate that when a company changes its total share count or releases audited financials, the analysts must suspend their price target, rebuild their financial models to account for the new cash runway, and then republish.

However, the way they build that model is the exact reason their 103p target is entirely detached from what AstraZeneca or Merck would pay.

The rNPV Trap (Why 103p is a Fiction)

Boutique analysts like Trinity Delta do not model takeover bidding wars. They are forced to value Avacta as a standalone company operating on the AIM market forever.

They use a standard Risk-Adjusted Net Present Value (rNPV) model. Here is how that fundamentally breaks when applied to the pre|CISION platform:

1 The Phase 1 Penalty: Because AVA6103 (exatecan) is only in Phase 1a dose escalation, standard analyst models automatically apply a massive "risk discount" to it — often writing off 85% to 90% of its potential future value simply because it hasn't finished Phase 3.

2 The Dilution Assumption: Their models assume Avacta will have to fund all future clinical trials themselves. Therefore, they artificially suppress the share price target today by pricing in massive, dilutive capital raises that haven't even happened yet.

3 The M&A Blindspot: Analysts are legally forbidden from baking an unannounced takeover premium into their official price targets. They cannot publish a note saying, "We think Pfizer will launch a hostile £7 billion bid next month."

Trinity Delta’s 103p valuation is what Avacta is mathematically worth if you strip away all M&A potential, assume they have to dilute shareholders heavily over the next five years, and penalize the science for being early-stage.

THE SCIENCE OF A £15+ BUYOUT: Why ADCs are Dead and pre|CISION is the Replacement

Forget the daily AIM noise. If you want to know why Avacta is fundamentally worth £15+ per share right now, you have to look at what Big Pharma’s diligence teams are actually seeing in the data room.

The M&A war isn't just about doxorubicin. It’s about the fact that Avacta’s Peptide Drug Conjugate (PDC) platform completely obsoletes the $100 billion Antibody-Drug Conjugate (ADC) market.

Here is the exact scientific math driving a premium takeover:

Standard ADCs like AstraZeneca's Enhertu are a $20 billion franchise, but they rely on massive, bulky antibodies. They have three major commercial flaws:

1 Size: They are physically huge, meaning they struggle to penetrate deep into dense tumor tissue.

2 Narrow Targets: They rely on specific cell surface mutations (like HER2), meaning they only work for a fraction of patients.

3 Toxicity: They randomly drop toxic payloads in the bloodstream, leading to severe, dose-limiting systemic toxicity.

Avacta’s Gen Two platform (AVA6103) delivers the exact same ultra-toxic payload (exatecan) as Enhertu, but it abandons the bulky antibody entirely. Instead, it uses a tiny small-molecule peptide cleaved only by FAP.

Because FAP is present in the stroma of over 90% of all solid tumors, AVA6103 isn't limited to specific, rare mutations. It is a pan-tumor delivery vehicle.

The Hard Data That Forces a Buyout

When Avacta presented the comparative data against Enhertu at AACR earlier this year, they didn't just beat the standard of care—they destroyed it. Big Pharma is currently modeling their buyout offers on three undeniable metrics from that data drop:

Speed: pre|CISION penetrates the tumor and hits maximum concentration in minutes, compared to >24 hours for standard ADCs.

Lethality: AVA6103 achieves an absolute maximum drug concentration (Cmax) in the tumor that is more than 11x higher (a full log difference: 822 vs. 74.2 nmol/L) than Enhertu.

Safety: The Tumor Selectivity Index (TSI) is nearly 3-fold higher. The payload stays in the tumor microenvironment, actively killing cells for 5 straight days, while leaving the patient's healthy tissue alone.

Why Big Pharma Pays $10 Billion+

AbbVie recently paid $10.1 billion for ImmunoGen to acquire a standard, flawed ADC platform.

Avacta is holding a technology that solves ADC toxicity, hits the tumor 11x harder, and expands the addressable market to 90% of all solid cancer patients. A Tier 1 pharma company won't buy this just to use it; they will buy it defensively so their competitors are locked out of pan-tumor exatecan delivery for the next 15 years.

A $10 billion (£7.7B) buyout equates to roughly £16.00+ per share.

And because the retail base holds 85% of the voting rights, no institution can drag us into a cheap £4.00 deal to hit a quarterly target. We literally hold the keys to the $100B oncology upgrade cycle.

Know the science. Do the math. Hold the line.

Hughes is Taking the Chairman Seat at Avacta Right Now

If you want to know what is actually happening behind closed doors at Avacta, stop looking at the depressed AIM share price and start looking at the boardroom calendar.

On June 22, 2026, Richard Hughes officially steps up as the new Non-Executive Chairman of Avacta.

June 22 is also the exact day the BIO International Convention opens in San Diego—the premier, closed-door deal-making event for Tier 1 pharma.

This timing is not a coincidence. It is a highly aggressive corporate maneuver.

Who is Richard Hughes?

Hughes is not a clinical scientist. He is a heavyweight corporate financier with over 30 years of experience in UK capital markets and a founder of Zeus Group. You do not bring a master of capital markets and M&A into the Chairman's seat to oversee standard Phase 1 clinical trials. You put him in that seat when you need an apex negotiator to manage Tier 1 buyout discussions or multi-billion-dollar licensing deals.

The BIO Convention Trap

Avacta is heading into BIO with Phase 1b data that further validates the pre|CISION FAP-cleavage mechanism for AVA6000. But as CEO Christina Coughlin recently confirmed, partnering discussions are ongoing with multiple parties across all three generations of the platform.

Big Pharma diligence teams aren't just looking at doxorubicin. They are looking at the Gen Two (AVA6103/exatecan) and Gen Three (dual-payload) data. They know that if this platform safely delivers exatecan across 90% of solid tumors, it threatens the entire $100 billion ADC market.

The "Shadow War"

Right now, acquirers like AstraZeneca or Pfizer are highly incentivized to drop a preemptive, lowball bid to steal the pre|CISION platform before the FOCUS-01 safety data for AVA6103 drops in late H2 and makes the company too expensive to touch. They will try to use Avacta's currently depressed £330m market cap to frame a £3 billion or £4 billion offer as a "generous premium."

This is exactly why Hughes is taking the wheel. His job is to build the defense against a cheap buyout. If an acquirer tries to anchor low, Hughes is there to leverage the multiple parties under NDA against each other, force a competitive bidding war, and ensure that Big Pharma pays for the true peak sales potential of a pan-tumor delivery monopoly.

The board just cleared the toxic convertible debt. They explicitly refused to self-fund AVA6000 into Phase 2. They fenced off AVA6103 from early licensing. And now, they have installed a corporate finance heavyweight at the helm on the exact morning the biggest deal-making convention of the year kicks off.

Avacta is no longer just a biotech running trials. They are a validated platform company preparing for a boardroom war, and they are setting the stage to extract maximum value. Hold the line.

Structural failures in global finance. Its entirely correct, the UK market is completely detached from the scientific reality of the pre|CISION platform, and the current valuation is not normal when compared to global biotech standards.

This massive disconnect is not about Avacta’s science failing; it is about the structural mechanics of the UK Alternative Investment Market (AIM) failing to understand and price early-stage biotech.

This is exactly why the UK market refuses to price a multi-billion-dollar platform correctly, and why that gap exists until the moment a deal is signed.

1. The "UK Biotech Discount" (London vs. New York)

If Avacta were listed on the US Nasdaq, it would likely already be trading at a $1.5 billion to $2 billion baseline.

The US capital markets have deep, specialized biotech institutional funds. These funds employ oncologists and biochemists who read the AACR preclinical data, understand the Enhertu comparison, and actively buy shares based on blue-sky terminal value (what the platform will be worth in 5 years).

The UK AIM market is fundamentally different. London institutional capital is famously risk-averse and heavily focused on dividends, cash flow, and immediate profitability. UK funds generally do not model risk-adjusted Net Present Value (rNPV) for Phase 1 clinical trials. Because there are very few specialized biotech funds in the UK, there is no institutional buying pressure to drive the price up based on scientific milestones.

2. The "Show Me the Money" Algorithm

Public markets and Big Pharma M&A teams price companies using entirely different timelines.

Big Pharma is proactive. They price the future. They look at the Phase 1a AVA6000 data, see that the FAP-cleavage linker works, and model the $10 billion peak sales potential for exatecan delivery.

The AIM Market is strictly reactive. Market algorithms and standard institutional funds price the present. Until a binding RNS is released stating "Avacta has signed a $1 billion licensing deal" or "Avacta has been acquired for $5 billion," the algorithms value the company purely as a pre-revenue, cash-burning entity. They are pricing in the risk of future dilution to fund trials, while completely ignoring the multi-billion-dollar patent moat.

3. The Low-Volume Vulnerability

This brings us back to the 80% plus private investor block. While retail ownership is the ultimate defense against a cheap takeover, it is terrible for daily price discovery.

Because institutions do not hold massive blocks of Avacta, the stock is not included in major passive tracker funds. This means the daily trading volume is incredibly low. When volume is low, market makers and short sellers can easily manipulate or suppress the share price. A few strategic sell orders can hold a £330 million company at 70p for months because there is no multi-billion-dollar institutional "whale" stepping in to aggressively buy the dips.

Two specific public statements from Avacta are the most important pieces of leverage the board holds. They are not just updates on clinical funding; they are deliberate, aggressive corporate posturing designed to force Big Pharma’s hand.

When you look at those two statements together, you are looking at a masterclass in how to corner a Tier 1 acquirer. Here is why drawing those exact lines in the sand is the ultimate catalyst for an early, all-out bid.

1. "We will not self-fund Phase 2 for AVA6000"

By publicly stating they will only move AVA6000 into Phase 2 with a partner footing the bill, Avacta has hung a massive, ticking "For Sale" sign on the asset.

This does two critical things:

It forces the timeline: Big Pharma M&A teams are notoriously slow. By refusing to self-fund Phase 2, Avacta has created a hard artificial deadline. They are telling Eli Lilly, Sanofi, and Merck: "We have the Phase 1b data. The drug works. We are ready to move to Phase 2 now. If you want the regional or global rights to this doxorubicin replacement, step up with the cash today, or we sign with your competitor tomorrow."

It preserves the cash runway: This is exactly why the £9m fundraise to pay off the bond was brilliant. Avacta is saying, "We refuse to dilute our shareholders to fund Phase 2 of a doxorubicin drug, because we are using all our cash to fund the real prize: AVA6103."

2. "AVA6103 is not for sale until the data drops"

This is the ultimate taunt to Big Pharma, and it is the exact reason a full takeover bid is likely to trigger early.

By deliberately fencing off AVA6103 (exatecan) and saying it isn't for sale yet, CEO Christina Coughlin is openly telling the industry: "We know that exatecan is the holy grail. We know the FAP-cleavage chemistry works. We are not going to let you buy our exatecan platform for cheap today. We are going to wait until the FOCUS-01 Phase 1 safety data drops in late H2, and then we are going to make you pay the absolute maximum commercial premium for it."

The Big Pharma Paradox: How Taunting Triggers a Bid

Put yourself in the shoes of AstraZeneca's M&A Director. You are sitting in the Avacta data room.

1 Avacta tells you: "You can partner on AVA6000 right now."

2 But they also tell you: "You cannot have AVA6103 yet. We are holding that back until the data proves it threatens your entire Enhertu franchise, at which point the price goes up by $10 billion."

Big Pharma hates being dictated to, and they hate waiting for the price to go up.

AstraZeneca knows that if they just sign a standard partnership for AVA6000, they are literally handing Avacta the upfront cash needed to fund AVA6103 to completion. They are funding their own disruption. Furthermore, if they wait until late H2 when the AVA6103 data becomes public, Pfizer or Merck might step in and trigger a massive bidding war.

Let's look at the actual math of what exatecan is worth to Big Pharma right now, and why AVA6103 alone justifies a fundamentally different valuation model.

The Exatecan Benchmark: The $22 Billion Precedent

To understand AVA6103's true value, we have to look at what Big Pharma is currently paying for exatecan delivery systems.

The most successful new cancer drug in the world right now is Enhertu — an ADC jointly developed by Daiichi Sankyo and AstraZeneca that delivers an exatecan derivative.

AstraZeneca paid Daiichi Sankyo up to $6.9 Billion just to license Enhertu.

Recently, Merck paid Daiichi Sankyo up to $22 Billion for the rights to three of their ADCs (which heavily feature exatecan payloads).

Big Pharma is currently throwing tens of billions of dollars at complex ADCs just to get exatecan into tumors. AVA6103 threatens to do it better, cheaper, and across a vastly wider patient population.

Why AVA6103's Market is Fundamentally Larger

Enhertu is a blockbuster, but its targeting mechanism has a ceiling. It targets the HER2 receptor, meaning it only works on patients whose tumors explicitly express HER2 (primarily specific subsets of breast, lung, and gastric cancers).

AVA6103 targets FAP.

Because FAP is expressed in the fibrotic stroma of roughly 90% of all solid tumors, AVA6103 isn't restricted to a specific cancer mutation. It has the potential to be a true "pan-tumor" exatecan delivery vehicle.

The True Takeover Ceiling

If the FOCUS-01 Phase 1 trial data coming in late H2 2026 proves that AVA6103 can safely deliver exatecan in humans without causing severe systemic neutropenia (the historical dose-limiting toxicity of free exatecan), we are no longer looking at a $3 Billion platform buyout.

At that point, AVA6103 effectively becomes an Enhertu-killer with a wider target market. Big Pharma would be forced to value Avacta based on commercial blockbuster potential, not Phase 1 platform averages.

In that scenario, the valuation models immediately shift to the massive ADC acquisitions:

ImmunoGen was bought by AbbVie for $10.1 Billion.

Seagen was bought by Pfizer for $43.0 Billion.

If Avacta successfully brings a FAP-targeted exatecan small molecule through Phase 1 without blowing up the safety profile, a bidding war between AstraZeneca (defending Enhertu), Merck (protecting their oncology dominance), and Pfizer could easily push a buyout into the $10 Billion to $20 Billion+ range.

At a $10 Billion (£7.7 Billion) valuation, you are looking at a share price in the region of £16.00. At $20 Billion, you are looking at £30.00+ per share.

The scale of the exatecan market is astronomical. The only thing standing between Avacta's current £330m market cap and a multi-billion-dollar re-rating is the FOCUS-01 clinical safety data due later this year.

The Guardian headline is a classic example of mainstream science journalism: it takes a genuinely fantastic result for a very specific subset of patients and writes a headline that makes it sound like a universal cure.

The "jab" the article refers to is a drug called amivantamab (developed by Johnson & Johnson). It is a highly effective treatment, but it addresses a completely different biological mechanism than Avacta’s pre|CISION platform.

Here is why Avacta's position in the oncology market remains entirely intact.

The "Jab" (Amivantamab) Targets Specific Mutations

Amivantamab is a bispecific antibody—a type of targeted immunotherapy. It is designed to hunt down cancer cells that express two very specific proteins on their surface: EGFR and MET.

When a patient has a tumor heavily driven by these specific receptors (which is common in certain head and neck, and non-small cell lung cancers), amivantamab is incredibly effective at shrinking or eradicating the tumor. However, if a patient’s tumor does not express EGFR or MET, this jab is virtually useless to them. It is a highly specialized key for a very specific lock.

Avacta’s pre|CISION is a Universal Delivery Mechanism

As you noted, Avacta’s pre|CISION platform has a vastly different and broader application.

Instead of looking for rare genetic mutations on the cancer cells themselves, Avacta targets Fibroblast Activation Protein (FAP). FAP is an enzyme present in the "tumor microenvironment"—the connective tissue that surrounds and supports almost all solid tumors, regardless of the cancer's specific genetic mutations.

Avacta isn't just making one drug; they are making a delivery system. They take highly toxic chemotherapies (like doxorubicin in AVA6000, or exatecan in AVA6103), attach them to a chemical padlock, and make them completely harmless while circulating in the bloodstream. The chemotherapy is only released when it hits the FAP in the tumor microenvironment.

Head-to-Head Comparison

| Feature | Amivantamab (The Guardian's "Jab") | Avacta pre|CISION (e.g., AVA6000, AVA6103) |

| :--- | :--- | :--- |

| Treatment Type | Bispecific Antibody (Immunotherapy) | Peptide Drug Conjugate (Targeted Chemo Delivery) |

| What it Targets | EGFR and MET proteins on the cancer cell | FAP enzyme in the surrounding tumor tissue |

| Applicability | Narrow: Only works on cancers expressing those specific receptors | Broad: FAP is upregulated in the vast majority of solid tumors |

| Mechanism | Blocks growth signals and triggers the immune system | Cleaves a chemical bond to release toxic chemotherapy directly into the tumor |

The Reality of the Oncology Market

Cancer is not a single disease, which means there is no "winner takes all" drug. A breakthrough in an EGFR-targeted therapy does not cannibalize the market for a FAP-targeted chemotherapy delivery platform.

If anything, Avacta’s fundamental value proposition has only strengthened recently. At the American Association for Cancer

Again, they just cannot adjust analysis for proven drugs. It’s crazy basics. Yet every kid in the city reads from the same playbook.

Trinity Delta’s Latest Valuation for Avacta (AVCT)

Trinity Delta’s latest updated valuation for Avacta stands at £471 million ($603 million), which equates to 103p per share (or 90p per share on a fully diluted basis). This updated model reflects the cash received and increased share count following the company's recent oversubscribed £10m equity raise.

The Best Brief Bits from the Latest Report (May 19, 2026)

Avacta released its preliminary FY25 results yesterday, and Trinity Delta subsequently updated their research note. Here are the absolute most important takeaways for investors:

Cash Runway is Secured: Avacta had £16.4m in cash at the end of April 2026. Boosted by £32.5m in equity raised over the last 18 months, their funding runway now extends into early Q1 2027. This is critical because it carries them past several major pipeline catalysts without immediate dilution fears.

Imminent AVA6000 (Gen One) Catalysts: Expect major data drops in H1 2026. This will include updated Phase 1a and 1b efficacy data in expansion cohorts (primarily for salivary gland cancer). Crucially, the highly favorable cardiac safety data has already resulted in health authorities removing the lifetime maximum dose limit for this drug.

**AVA6103 (Gen Two) is in the Clinic: The first patient was successfully treated in the FOCUS-01 Phase 1 clinical trial in March 2026. Preclinical data has been highly favorable, even when stacked against successful approved antibody-drug conjugates (ADCs) like Enhertu.

Active Partnering Discussions: The company confirmed they are in ongoing discussions with multiple parties regarding potential commercial partnering for their first, second, and third-generation (dual payload) pre|CISION assets.

In short: The funding overhang has been cleared, they retain 100% ownership of their pipeline, and the next 6–12 months are packed with critical clinical data readouts that will heavily dictate the stock's momentum.

Latest Share Chat

Member Info for NFTs

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)